Translational Development Acquisition Corp. is a special purpose acquisition company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It currently has no significant operations. The company was incorporated to identify and combine with a suitable operating business.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | 1.6 | — |
| Q3 2025 | 0 | — | 1.7 | — |
| Q4 2025 | 0 | — | 1.6 | — |
| Q1 2026 | 0 | — | 1.3 | — |
| Q2 2026 | 0 | — | 0.9 | -41.7% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Zentalis Pharmaceuticals, Inc. (ZNTL), Chicago Atlantic BDC, Inc. (LIEN), ZenaTech, Inc. (ZENA), MacroGenics, Inc. (MGNX), Jones Ventures INTL Acquisition1 Corp (JONE), HMH Holding Inc. (HMH)